Trial Profile
Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs BI 671800 (Primary) ; Montelukast
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 20 Mar 2012 This trial has been recruiting in Austria as reported by European Clinical Trials Database record.
- 22 Feb 2012 Planned number of patients changed from 345 to 700 as reported by European Clinical Trials Database record.